Aakaar Medical Technologies Ltd. (NSE:AAKAAR) announced strong profits, but the stock was stagnant. We did some digging, and we found some concerning factors in the details.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Examining Cashflow Against Aakaar Medical Technologies' Earnings

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.

As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".

Aakaar Medical Technologies has an accrual ratio of 0.41 for the year to September 2026. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of free cashflow in that time. Over the last year it actually had negative free cash flow of ₹172m, in contrast to the aforementioned profit of ₹109.6m. We also note that Aakaar Medical Technologies' free cash flow was actually negative last year as well, so we could understand if shareholders were bothered by its outflow of ₹172m.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Aakaar Medical Technologies.

Our Take On Aakaar Medical Technologies' Profit Performance

As we discussed above, we think Aakaar Medical Technologies' earnings were not supported by free cash flow, which might concern some investors. For this reason, we think that Aakaar Medical Technologies' statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But the good news is that its EPS growth over the last three years has been very impressive. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. To that end, you should learn about the 2 warning signs we've spotted with Aakaar Medical Technologies (including 1 which shouldn't be ignored).

This note has only looked at a single factor that sheds light on the nature of Aakaar Medical Technologies' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.